Engflag

Pregadoc NT

Quick links to important sections

Pregadoc NT

Pregadoc NT_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pregadoc NT

Property Description
Active Ingredients Nortriptyline, Pregabalin
Form Oral capsule or tablet
Pharmacological Class Neuropathic Pain Agent, Psychoactive Analgesic Combination
Common Use Chronic pain management
Origin Synthetic compound

What Type of Medicine is Pregadoc NT? (Classification and Form)

Pregadoc NT is defined as a synthetic, fixed-dose combination (FDC) medicine, available exclusively by prescription, and provided as an oral formulation, typically a tablet or capsule. Its identity is established by its two active ingredients: Nortriptyline, classified as a tricyclic antidepressant (TCA), and Pregabalin, a gabapentinoid. The combination is categorized as a Neuropathic Pain Agent due to its specific target on nerve-related discomfort, utilizing two distinct mechanisms of action within a single unit. The Pregabalin component is utilized for managing neuropathic pain, an application which is broadly accepted and clinically recognized across therapeutic guidelines.

Composition: The Combination of Nortriptyline and Pregabalin

The medicine contains the active ingredients Nortriptyline and Pregabalin, leveraging their complementary effects to modulate central nervous system activity. Nortriptyline works by inhibiting the reuptake of chemical messengers, aiding the brain's natural pain-inhibitory pathways. Pregabalin, conversely, binds to specific sites on nerve cells to calm their overactivity. In the treatment of chronic pain conditions, combinations of TCAs and GABA analogues (like Pregabalin) are used to achieve a greater analgesic effect than either drug alone. This combined strategy is frequently employed for individuals experiencing consistent, debilitating pain that originates from nerve dysfunction. The combination is formulated with specific pharmaceutical excipients necessary to ensure the stability and proper delivery of the active ingredients within the solid oral dosage form.

The General Purpose of This Dual-Action Approach

The core therapeutic purpose of this dual-action strategy is to manage complex, persistent pain conditions, specifically focusing on the mechanisms of sustained neuropathic pain. By combining agents that address both the electrical signaling and the chemical balance of pain transmission, the medicine is designed to achieve a synergistic effect. This multimodal approach is intended to stabilize nerve functionality and restore the chemical environment necessary to inhibit excessive pain transmission, thereby offering a comprehensive approach to pain management.

What side effects are possible with Pregadoc NT?

Possible Side Effects and Safety Information

The safety profile for Pregadoc NT, a combination medicine, is based on officially documented adverse reactions derived from government regulatory sources. Side effects are classified by their frequency and organized by the affected body system (System-Organ-Class or SOC).

Frequency-Classified Adverse Reactions

Classification Examples of Documented Side Effects
Very Common (ge 1/10) Dizziness, Somnolence (Drowsiness)
Common (ge 1/100 to <1/10) Weight increased, Vision blurred, Dry mouth, Peripheral oedema, Confusion, Nausea

Serious Adverse Reactions

Regulatory documents highlight rare but clinically important events. These include Angioedema (severe swelling of the face, throat, or neck), Severe Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson syndrome, and an increased risk of Suicidal Ideation and Behaviour. Cases of Respiratory Depression have been reported, particularly when used with other Central Nervous System depressants.

Population-Specific Safety Considerations

Specific cautions are noted for certain groups. Elderly patients may have an increased risk of falls and congestive heart failure. Patients with Renal Impairment require careful dose adjustment, as the drug's component is primarily excreted by the kidneys. Use during Pregnancy and Lactation is generally not recommended unless the benefit outweighs the potential risk.

Safety Restrictions and Patterns

The medication must not be stopped suddenly; treatment requires gradual tapering to avoid withdrawal symptoms (e.g., anxiety, insomnia, headache). Caution is required when using the medication with other CNS depressants or opioids. The drug's component adverse reactions and discontinuation rates are often dose-related.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose with Pregadoc NT (Nortriptyline/Pregabalin) as potentially leading to severe and life-threatening conditions, primarily affecting the Central Nervous System (CNS) and Cardiovascular System. All suspected overdoses mandate seeking immediate medical attention or contacting emergency services.

Documented Overdose Manifestations

Overdose may present with CNS effects including severe drowsiness (somnolence), profound confusion, slurred speech, agitation, and loss of consciousness. Cardiovascular signs documented include tachycardia (fast heart rate) and hypotension (low blood pressure).

Severe Outcomes and Emergency Actions

The most serious documented outcomes are cardiotoxicity, which can lead to ventricular dysrhythmias, QRS complex widening on an ECG, and potentially cardiac arrest. Neurological risks include generalized seizures and respiratory depression. The potential for Serotonin Syndrome is also recognized in regulatory documentation.

Immediate medical help is required upon the onset of seizures, an irregular heart rhythm, or profound CNS depression. There is no specific antidote known or documented for this overdose. Management listed in official labels includes general supportive care, gastrointestinal decontamination (e.g., activated charcoal), and continuous ECG monitoring due to the severe cardiac risks.

Therapeutic Uses of Pregadoc NT

What Pregadoc NT Treats: Main Uses and Benefits

This medication is commonly used to help with persistent nerve pain and the intense sensory disturbances that arise from nerve damage. It is applied in addressing pronounced symptoms related to physical discomfort, such as burning sensations, shooting pain, tingling, and numbness.

The combination is commonly used to help with conditions characterized by periods of heightened symptoms, such as diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia. It plays a role in managing symptoms that interfere with daily comfort and may assist with secondary symptoms related to systemic imbalance, such as sleep disruption and associated anxiety.

The goal of this management strategy is to support the patient during difficult symptomatic episodes by easing distress.

The medication is relevant for easing symptoms that become more disruptive during flare-ups, such as moderate to severe neuropathic pain. It is applied in settings where additional management of discomfort is required, and assists with maintaining functional stability.

Quick Fact: Relief for Sensory Nerve Pain The combination may assist with challenging sensory manifestations of nerve damage, including sudden stabbing and burning pain episodes.

Eligibility and Restrictions for Use

The eligibility profile for Pregadoc NT is defined by constraints derived from its active ingredients, Nortriptyline and Pregabalin, as stated in official regulatory documentation. Use is established for adults who do not possess specific contraindications.

Absolute Non-Eligibility (Contraindications)

This medicine must not be used by patients with a known hypersensitivity to any component of the formulation. It is strictly contraindicated for use in patients taking a Monoamine Oxidase Inhibitor (MAOI), or within 14 days of discontinuing an MAOI. Additionally, it is prohibited for patients during the acute recovery period following a myocardial infarction (heart attack) or those with existing severe cardiac arrhythmias.

Conditional Use and Age Restrictions

Use is not established or not recommended for children and adolescents under 17 years. Older adults may require dose adjustment due to likely reduced renal function. Patients with renal impairment require a mandatory dose reduction based on their kidney function. Patients with pre-existing cardiovascular disease or angle-closure glaucoma require specific supervision.

Pregnancy and Lactation Status

Pregadoc NT should not be used in women who are pregnant or planning pregnancy unless the benefit clearly outweighs the potential risk. Breastfeeding is not recommended; a decision must be made to discontinue nursing or discontinue the therapy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with other medicinal products for Pregadoc NT are officially documented across several regulatory categories, primarily related to pharmacodynamic effects and metabolic clearance.

Formal Restrictions and Timing

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and intravenous Methylene Blue, is strictly contraindicated. The regulatory label requires a mandatory 14-day washout period after discontinuing MAOI therapy before initiating Nortriptyline treatment. The Pregabalin component may be taken with or without food, as its absorption is not clinically affected.

Pharmacodynamic Interactions

The most significant pharmacodynamic interactions involve substances that cause Central Nervous System (CNS) depression. Co-administration with agents such as opioids, benzodiazepines, sedatives, and alcohol may result in an additive effect, carrying a formal warning for an increased risk of respiratory depression. Additionally, combining this medicine with other serotonergic agents (e.g., SSRIs, triptans) increases the officially documented risk of serotonin syndrome.

Pharmacokinetic and Population Considerations

The Nortriptyline component is subject to metabolic interactions via the CYP2D6 enzyme. Co-administration with CYP2D6 inhibitors (e.g., Quinidine) is documented to increase Nortriptyline plasma concentration by reducing its clearance. Conversely, strong CYP inducers (e.g., Rifampin) can reduce its serum levels. This pharmacokinetic profile requires consideration for patient populations, as the Pregabalin dose requires adjustment based on creatinine clearance in cases of renal impairment.

Mechanism of Action

The mechanism of action involves employing two distinct, synergistic pharmacodynamic mechanisms that target different sites within the nociceptive signaling network.

Modulating Pathological Neuronal Hyperexcitation

The Pregabalin component acts as a functional modulator by binding to the alpha2delta subunit of presynaptic Voltage-Gated Calcium Channels. This molecular interaction reduces the influx of calcium ions, which decreases the synaptic release of excitatory neurotransmitters like glutamate. The resulting physiological effect is the suppression of pathological neuronal hyperexcitation, dampening the excessive, rapid firing of damaged neurons that contribute to excessive signal propagation.

Enhancing Endogenous Pain Inhibition

The Nortriptyline component functions as a reuptake inhibitor of Norepinephrine and Serotonin. By blocking the reabsorption of these key messengers, it increases their synaptic concentration in the spinal cord. This strengthens the functional activity of the Descending Inhibitory Pain Pathway, thereby increasing the functional output of the descending inhibitory pathway and contributing to a regulated inhibitory tone.

Coordinated Signal Modulation (Synergy)

The combination provides a coordinated mechanism: one component reduces the throughput of the excessive excitatory signal while the other enhances the central inhibitory influence on signal propagation. This dual-level action contributes to the modulation of nerve excitability that influences the balance between excitatory and inhibitory signaling.

Dosage and Administration Information

How to Use Pregadoc NT: Official Administration Guidelines

Pregadoc NT, a fixed-dose combination, is administered exclusively via the oral route as a tablet or capsule. The total daily dosage is typically taken in divided portions, most commonly twice daily, and intake is permissible with or without food. For consistency, it is recommended that the medication be taken at a fixed time each day. The solid dosage form must be swallowed whole and should not be crushed, broken, or chewed.

Dosing Schedule and Adjustment Principles

Treatment is initiated with a low initial dose to allow for gradual adjustment. The official dosing strategy is defined by a principle of gradualism and controlled titration. For the Pregabalin component, the typical starting dose for neuropathic pain is 150 mg per day, which can be slowly increased over a minimum of three to seven days to a maintenance range of 150 mg to 600 mg daily. The maximum dose for the Nortriptyline component should not exceed 150 mg per day.

Population-Specific and Discontinuation Rules

Administration requires specific adjustments for patient populations with impaired renal function, as the Pregabalin component is primarily cleared by the kidneys. Individuals with renal impairment require a modified dose based on their creatinine clearance, and those undergoing haemodialysis require a supplemental dose after each treatment session. For older adults, a lower starting dose, such as 10 to 20 mg daily for the Nortriptyline component, is typically used. Should discontinuation of therapy become necessary, the medicine must be tapered gradually over a minimum of one week to avoid procedural issues, regardless of the treatment duration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pregadoc NT

Evidence for Use in Painful Diabetic Peripheral Neuropathy (DPN)

The research base for the fixed-dose combination of Pregabalin and Nortriptyline (Pregadoc NT) for painful DPN includes short-term Randomized Controlled Trials (RCTs) and multi-centric, open-label observational studies. These studies were applied in research contexts involving adults with DPN. The primary focus was on outcomes related to physical discomfort (e.g., changes in pain intensity on numerical scales) and outcomes related to systemic or functional imbalance (e.g., sleep interference) were studied. Evidence is limited regarding symptom patterns extending beyond the initial 12-week trials, and few data are available from large-scale RCTs dedicated exclusively to this specific combination medicine.

Evidence for Use in Postherpetic Neuralgia (PHN)

The combination was studied for PHN, a condition involving periods of heightened symptoms. The research includes short-term controlled trials that compared the FDC against monotherapy. Studies monitored change in pain intensity and outcomes describing episodic or acute changes in the quality of specific symptoms, such as burning sensation. Findings indicate that outcomes related to sleep interference were also monitored. The sample sizes were limited in these controlled trials, and the studies generally featured limited follow-up durations, meaning long-term effects are not fully established for the combination in this context.

Follow-up Duration and Extended Data

Research has generally focused on research exploring short-term symptom changes in patient-reported experiences. The key efficacy assessments in controlled trials have been observed in defined time intervals, typically concluding at 4, 8, or 12 weeks. While some retrospective data on the component drugs may extend up to 12 months, there is limited information for long-term outcomes specifically for the fixed-dose combination. Long-term effects are not fully established over periods of six months or more.

Evidence in Specific Patient Groups

The studies primarily focused on the general adult population. Data for certain groups remain insufficient. For instance, there is limited published information available to describe outcomes related to physical discomfort in children or adolescents. Similarly, data describing outcomes in frail elderly populations or patients with significant renal impairment remain limited.

Understanding Research Gaps and Limitations

The research conducted so far contributes to the broader evidence landscape. A key limitation is the limited follow-up durations and modest sample sizes of many controlled trials focused on the FDC. Evidence quality varies across studies, and comparative evidence is lacking for certain standard monotherapy drugs against the FDC.

Key Studies & References Neuropathic pain in adults: pharmacological management in non-specialist settings (NICE Guideline NG59)

Frequently Asked Questions (FAQ)

Common questions about Pregadoc NT (FAQ)

Q: What are the most common reasons a doctor might prescribe Pregadoc NT?

Official regulatory documents state that this fixed-dose combination medicine is officially indicated for the management of neuropathic pain. This includes conditions such as painful Diabetic Peripheral Neuropathy (DPN) and Postherpetic Neuralgia (PHN).

Q: Is Pregadoc NT used for nerve-related issues?

Yes, the medicine is officially indicated for the management of neuropathic pain, a type of chronic pain caused by damaged or malfunctioning nerves. Its mechanism involves modulating nerve excitability to influence pain signaling.

Q: What is the main difference between Pregadoc NT and other similar medicines?

Official documents describe this medicine as a fixed-dose combination that is unique due to its dual mechanism of action. One component works by influencing calcium channels, and the other component enhances inhibitory pathways, providing a coordinated signal modulation.

Q: Do studies suggest that Pregadoc NT is effective for its intended purpose?

Regulatory documents contain evidence from controlled trials which supported the approval of the drug for its stated indications. These studies demonstrated positive outcomes related to pain relief and other functional measures such as sleep interference.

Q: How long does it typically take for a person to notice the effects of Pregadoc NT?

While the component drugs are absorbed quickly, regulatory information indicates that the full therapeutic benefit in studies has typically been observed developing over one to two weeks. Official guidelines describe initiation with a low dose and gradual adjustment.

Q: How quickly does the effect of Pregadoc NT wear off?

The elimination of this medicine from the body is influenced by its two components. The component Pregabalin has an elimination half-life of approximately 6.3 hours, while the Nortriptyline component has a significantly longer half-life, contributing to the drug's sustained action.

Q: Is Pregadoc NT safe for long-term use?

Research evidence, as documented in regulatory sources, has primarily focused on short-term outcomes, often within 12 weeks. Official documents note that evidence from clinical trials on the effects of use exceeding six months is limited.

Q: What age groups is Pregadoc NT generally prescribed for?

The combination product is primarily studied and indicated for use in the adult population. Official regulatory documents state that the safety and effectiveness of this medicine have not been established in patients under 18 years of age.

Q: Can older adults use Pregadoc NT, and are there special considerations?

Official documents note that a lower starting dose may be used for older adults due to potential increased sensitivity to side effects. Regulatory warnings also cite an increased risk of specific events, such as falls and congestive heart failure, in this population.

Q: Can I take Pregadoc NT if I have diabetes?

The medicine is indicated for painful Diabetic Peripheral Neuropathy (DPN), which is nerve damage related to diabetes. However, regulatory warnings also advise monitoring blood glucose levels, as the drug may affect them.

Q: Does Pregadoc NT require any special monitoring while being used?

Official documentation recommends close monitoring for changes in mood or behavior and potential suicidal ideation. Dosage adjustments also require monitoring of kidney function (creatinine clearance).

Q: Can Pregadoc NT be used by people with a history of heart problems?

The Nortriptyline component carries warnings for patients with a history of cardiovascular disease. This includes a risk of QT interval prolongation and potential effects on blood pressure and heart rate.

Q: What is the pregnancy safety category for Pregadoc NT?

Official information states that use during pregnancy is generally not recommended unless the potential benefit is determined to justify the potential risk to the fetus. The use during lactation is also subject to caution.

Q: What kind of research has been done on Pregadoc NT in children or adolescents?

Official regulatory documents state that the safety and effectiveness of this medicine have not been established in patients under 18 years of age. Research data for this group remains insufficient.

Q: Does Pregadoc NT cause changes in mood or personality?

Regulatory documents include warnings about the risk of suicidal ideation and behavior and other severe mood or behavioral changes associated with the components. Regulatory documents recommend close monitoring for such changes.

Q: What is the risk of dependence or addiction with Pregadoc NT?

The regulatory label includes a warning regarding the potential for physical and psychological dependence and abuse, associated with the Pregabalin component. This risk is noted particularly with prolonged use.

Q: Is Pregadoc NT considered a narcotic or controlled substance?

The Pregabalin component is classified in the United States as a Schedule V controlled substance. It is not classified as a narcotic (opioid), but it is subject to regulation due to its potential for abuse.

Q: Is there a link between Pregadoc NT and weight gain or loss?

Regulatory documents list weight increased as a common adverse reaction associated with use of the medicine. Changes in appetite, specifically increased appetite, have also been reported.

Q: Is it normal to feel a change in appetite after starting Pregadoc NT?

Regulatory safety data lists common adverse reactions for the component drugs which include increased appetite in some patients. This potential change is often associated with the documented adverse reaction of weight gain.

Q: Is it normal to feel dizzy when first starting Pregadoc NT?

Dizziness and somnolence (drowsiness) are listed as very common adverse reactions in official documents. These effects are particularly noted when therapy is initiated or when the dose is increased.

Q: Can Pregadoc NT cause strange or vivid dreams?

Adverse reaction listings for the component drugs, as found in regulatory documents, include reports of abnormal dreams and nightmares.

Q: Does taking Pregadoc NT make you more sensitive to the sun?

The Nortriptyline component belongs to a class of medicines associated with a potential risk of photosensitivity reactions. Official regulatory warnings note that patients should limit sun exposure while using this medicine.

Q: Does Pregadoc NT have to be taken at a specific time of day?

Official guidelines recommend taking the medication at a fixed time each day for consistency. Due to the potential for dizziness and drowsiness, administration in the evening or at bedtime is often described in relation to managing potential drowsiness.

Q: Do I need to change my diet while using Pregadoc NT?

Official documentation states that this medicine can be taken with or without food. There are no specific dietary restrictions required for the product’s function.

Q: Can Pregadoc NT be taken with antacids or heartburn medication?

Official information indicates that the Pregabalin component has no known significant interaction with antacids.

Q: Are there any known interactions between Pregadoc NT and common pain relievers?

Official warnings describe potential pharmacodynamic interactions with other agents that cause Central Nervous System (CNS) depression, which include opioids and some over-the-counter pain relievers. This co-administration may result in an additive effect.

Q: Can Pregadoc NT affect the results of blood tests?

Regulatory data warns of potential increases in creatine kinase levels and possible effects on blood glucose levels. The Nortriptyline component may also affect certain laboratory parameters, such as ECG readings and liver function tests.

Q: Is there a generic version of Pregadoc NT available?

While Pregadoc NT is the brand name for the fixed-dose combination, its two component drugs, Pregabalin and Nortriptyline, are both widely available as generic medicines.

Q: What are the official sources of information about Pregadoc NT?

Official, authoritative sources include the drug's Full Prescribing Information or Summary of Product Characteristics (SmPC). These documents are provided by government agencies such as the FDA, EMA, Health Canada, and NIH MedlinePlus.

Q: How is Pregadoc NT different from a regular anti-anxiety medicine?

Although one component of Pregadoc NT can affect neurotransmitters, the medicine is officially indicated for neuropathic pain. Its primary mechanism is focused on modulating nerve excitability to influence pain signaling, differentiating it from the primary use of most anti-anxiety medicines.

How should Pregadoc NT be stored and disposed of?

Storage Conditions and Environmental Control

Pregadoc NT must be stored at room temperature, generally defined as between mathbf10 C and mathbf25 C or kept below mathbf30 C.

Requirement Condition
Temperature Store below 30 C (Do not freeze)
Protection Keep in a cool, dry place; protect from light and moisture
Container Store in the original container/pack
Child Safety Keep out of the sight and reach of children

Disposal Instructions

Any expired or unused Pregadoc NT must be managed as special pharmaceutical waste.

Do not flush the medication down the toilet or throw it into household trash unless specifically instructed to do so by the regulatory document. The product must be disposed of in special ways following local regulations to prevent accidental consumption by children, pets, or others.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Pregadoc NT found in:

A-Z Index: